Improved outcome of refractory langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan

Bone Marrow Transplantation

Volumn 45, Issue 5, 2010, Pages 901-906

  Kudo, K ^a,j   Ohga, S ^b,j   Morimoto, A ^c,j   Ishida, Y ^d,j   Suzuki, N ^e,j   Hasegawa, D ^f   Nagatoshi, Y ^g   Kato, S ^h,k   Ishii, E ^i,j  

^a SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^e SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Hyogo Children's Hospital   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j HLH/LCH Committee in the Japanese Society of Pediatric Hematology   (Japan)

^k SCT Committee in the Japanese Society of Pediatric Hematology   (Japan)

more..

Author keywords

Langerhans cell histiocytosis; Reduced intensity conditioning; Refractory; Stem cell transplantation

Indexed keywords

CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; PIRARUBICIN; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINBLASTINE; VINCRISTINE;

ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM; HISTIOCYTOSIS X; HUMAN; JAPAN; LIVER; LUNG; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SPLEEN; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; INFANT, NEWBORN; JAPAN; MALE; SURVIVAL RATE; TISSUE DONORS; TREATMENT OUTCOME;

EID: 77952423394     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.245     Document Type: Article

References (17)

1. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program 2004, 283-296.
2. Stephan JL. Histiocytoses. Eur J Pediatr 1995;154:600-609.
3. Henter JI, Tondini C, Pritchard J. Histiocyte disorders. Crit Rev Oncol Hematol 2004;50:157-174.
4. Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H, DAL-HX Study Group. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 2002;39:581-585.
5. Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001;138:728-734.
6. Gadner H, Grois N, Pötschger U, Minkov M, Arico M, Braier J et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008;111:2556-2562.
7. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group. Arch Dis Child 1996;75:17-24.
8. Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006;107:613-619.
9. Bernard F, Thomas C, Bertrand Y, Munzer M, Landman Parker J, Ouache M et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005;41:2682-2689.
10. Steiner M, Matthes-Martin S, Attarbaschi A, Minkov M, Grois N, Unger E et al. Improved outcome of treatmentresistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005;36:215-225.
11. Caselli D, Aricò M, EBMT Paediatric Working Party. The role of BMT in childhood histiocytoses. Bone Marrow Transplant 2008;41: S8-S13.
12. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
13. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep. cancer.gov), Publish Date: December 12, 2003.
14. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187-193.
15. Ringden O, Ahstrom L, Lonnqvist B, Båryd I, Svedmyr E, Gahrton G. Allogeneic bone marrow transplantation in a patient with chemotherapy-resistant progressive histiocytosis X. N Engl J Med 1987;316:733-735. (Pubitemid 17036479)
16. Kinugawa N, Imashuku S, Hirota Y, Yamada K, Yamamoto A, Akazai A et al. Hematopoietic stem cell transplantation (HSCT) for Langerhans cell histiocytosis (LCH) in Japan. Bone Marrow Transplant 1999;24:935-938. (Pubitemid 29500359)
17. Steiner M, Matthes-Martin S, Attarbaschi A, Lawitschka A, Minkov M, Mittheisz E et al. Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis. Haematologica 2007;92: e3-e4.